Atopic Dermatitis

>

Latest News

FDA extends review of ruxolitinib cream for pediatric atopic dermatitis | Image credit: Contemporary Pediatrics.
FDA extends review of ruxolitinib cream for pediatric atopic dermatitis

June 20th 2025

The FDA has extended the review of ruxolitinib for atopic dermatitis in children 2 to 11 years to September 2025 to evaluate new CMC data.

John Browning, MD, explains dermatological questions to ask, answer in primary care
John Browning, MD, explains dermatological questions to ask, answer in primary care

June 19th 2025

Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more
Weekly review: Clesrovimab for RSV approved, new dupilumab data, and more

June 13th 2025

First infant enrolled in trial of roflumilast 0.05% for atopic dermatitis in infants | | Image Credit: © Dinko - © Dinko- stock.adobe.com.
First infant enrolled in trial of roflumilast cream, 0.05% for atopic dermatitis in infants

June 10th 2025

Dupilumab improves atopic dermatitis severity in adolescents, adults with skin of color | Image Credit: © this_baker - © this_baker - stock.adobe.com.
Dupilumab improves atopic dermatitis severity in adolescents, adults with skin of color

June 9th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.